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Abstract
Epstein-Barr virus (EBV) infection is associated with several human malignancies. Interferon (IFN) regulatory factor 7 (IRF-7)
has several splicing variants, and at least the major splicing variant (IRF-7A) has oncogenic potential and is associated with
EBV transformation processes. IRF-7C is an alternative splicing variant with only the DNA-binding domain of IRF-7. Whether
IRF-7C is present under physiological conditions and its functions in viral transformation are unknown. In this report, we
prove the existence of IRF-7C protein and RNA in certain cells under physiological conditions, and find that high levels of
IRF-7C are associated with EBV transformation of human primary B cells in vitro as well as EBV type III latency. EBV latent
membrane protein 1 (LMP-1) stimulates IRF-7C expression in B lymphocytes. IRF-7C has oncogenic potential in rodent cells
and partially restores the growth properties of EBV-transformed cells under a growth-inhibition condition. A tumor array
experiment has identified six primary tumor specimens with high levels of IRF-7C protein—all of them are lymphomas.
Furthermore, we show that the expression of IRF-7C is apparently closely associated with other IRF-7 splicing variants. IRF-
7C inhibits the function of IRF-7 in transcriptional regulation of IFN genes. These data suggest that EBV may use splicing
variants of IRF-7 for its transformation process in two strategies: to use oncogenic properties of various IRF-7 splicing
variants, but use one of its splicing variants (IRF-7C) to block the IFN-induction function of IRF-7 that is detrimental for viral
transformation. The work provides a novel relation of host/virus interactions, and has expanded our knowledge about IRFs
in EBV transformation.
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Introduction
Epstein-Barr virus (EBV) infection has been associated with the
development of several human malignancies, including nasopha-
ryngeal carcinoma (NPC), Burkitt’s lymphoma (BL), Hodgkin’s
lymphoma, T cell lymphoma, and gastric carcinoma [1,2]. In
immunocompromised individuals, such as organ transplant
recipients and AIDS patients, EBV almost certainly triggers two
fatal cancers without the necessity for cofactors: AIDS-associated
central nervous system (CNS) lymphoma and post-transplantation
lymphoproliferative disorder (PTLD) [3].
EBV establishes several distinctive types of latencies in host
cells. In typeIlatency, EBV nuclear antigen 1(EBNA1)and small
EBV-encoded, non-polyadenylated nuclear RNAs (EBER-1 and
-2) are expressed in host cells. In contrast, six nuclear proteins
(EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and
EBNA-LP), three membrane proteins (latent membrane protein
1 [LMP-1], LMP-2A, and LMP-2B), plus EBERs are expressed
in type III latency [1,2].
EBV transforms adult primary B cells into continually growing
lymphoblastoid cell lines (LCLs) and concomitantly establishes
type III latency in vitro. LMP-1 is required for the transformation
process of B lymphocytes [4,5,6]. LMP-1 acts as a constitutively
active, receptor-like molecule that does not need the binding of a
ligand [7], and appears to be a central effector of altered cell
growth, survival, adhesive, invasive and antiviral potential
[8,9,10,11,12,13,14].
Interferon (IFN) regulatory factors (IRF) are a small family of
transcription factors with multiple functions [15,16,17,18,
19,20,21,22]. IRF-7 was first cloned in the context of EBV latency
through its binding to an EBV latency promoter (Qp), which
regulates expression of EBNA1 [23]. IRF-7 is predominantly
expressed in the spleen, thymus and primary blood lymphocytes
(PBL) as a lymphoid-specific factor [23]. Currently it is established
that IRF-7 has four splicing variants designated as IRF-7A, IRF-7B,
IRF-7C, and IRF-7H [23,24]. By now, most of published papers
about IRF-7 focused on IRF-7A, the major splicing variant. Other
than in the negative regulation of viral promoter (Qp), IRF-7 also
positivelyregulatescellularTap-2aswellasviralLMP-1promotersin
EBV latency [25,26]. IRF-7 and EBV has intimate relations: EBV
both induces the expression of and activates (by phosphorylation and
nuclear translocation) IRF-7 in viral latency program [21,27]. In
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mas and has oncogenic properties [28]. Other than functioning in
EBV transformation, IRF-7 is a master gene involved in the
activation of type I IFN genes that are the key mediators of the host
innate immunity [29].
In this report, we have studied the functions of a splicing variant
of IRF-7. IRF-7C is an alternative splicing variant that the original
open-reading frame of IRF-7 has been changed. IRF-7C has only
the DNA binding domain with 165 amino acids and unique 13-
amino acids at the C-terminus [23]. Whether IRF-7C is present
under physiological conditions is unknown. Here, we have
generated an IRF-7C-specific antibody and find that IRF-7C is
associated with EBV transformation of primary B lymphocytes in
vitro and is highly expressed in some human primary lymphomas in
vivo. IRF-7C is expressed proportionally to other IRF-7 splicing
variants, and IRF-7C blocks the activation of IFN by IRF-7.
Because IRF-7 is activated in EBV transformation and activated
IRF-7 is known to induce the expression of IFNs, which is
detrimental to transformation. Thus, EBV may use both IRF-7
splicing variants for its oncogenic transformation, but uses one of
its splicing variants (IRF-7C) to block the detrimental IFN-
induction function of IRF-7.
Materials and Methods
Plasmids and Antibodies
Expression plasmids of IRF-7C, LMP-1, or its signaling
defective mutant, LMP-DM, and full-length IRF-7 antibody were
described previously [23,30]. IRF-7CD was made by a PCR to
remove the last 13-amino acids of IRF-7C, and cloned into
pcDNA3 vector. IRF7C-K92E plasmid was obtained with the use
of a PCR mutagenesis kit (Invitrogen). LMP-1 Ab (CS1-4)
antibodies were purchased from DAKO. GAPDH (0411) antibody
was purchased from Santa Cruz Biotechnology. Tubulin antibody
was purchased from Sigma. Rabbit IRF-7C antibody was
obtained by synthesizing the polypeptide with the last C-
terminus15 amino acid sequence of the IRF-7C, including the
unique 13 amino acid sequence that is not present in other three
splicing variants IRF-7A, -7B and -7H. The peptide was
conjugated to a carrier and used as the target for antibody
production (Pacific Immunology Corp).
Cell Culture, Interferons, and Sendai Virus
293T is a human fibroblast line (from ATCC) and were grown
in Dulbecco’s modified Eagle medium (DMEM, Gibco BRL)
supplemented with 10% fetal bovine serum (FBS; Gibco BRL) and
1% Penicillin-streptomycin (PS) at 37uC in a 5% CO2 incubator.
DG75 is an EBV-negative Burkitt’s lymphoma (BL) cell line [31].
BL41 is an EBV-negative BL line, BL41-EBV was generated by in
vitro infection of BL41 with EBV B95-8 strain [32]. Sav I, Sav III
are genetically identical cell lines that differ only in their latency
types [33]. The THP-1 cell line (Human acute monocytic
leukemia cell line) is derived from the peripheral blood of a 1
year old human male with acute monocytic leukemia [34]. These
cells were maintained in RPMI-1640 plus 10% fetal bovine serum
(FBS). Primary B cells and EBV-transformed B cell lines are
described [35]. Primary B cells isolation was done as described
with the use of CD19 antibody conjugated magnetic beads (Dynal
Inc) [28]. NIH3T3 cells were purchased from ATCC, and
maintained in DMEM plus 10% Calf Bovine Serum (CBS).
Recombinant human IFN-a was purchased from R & D Systems.
100 units of IFN were used for the treatment of cells. Sendai virus
stock was purchased from Spafas, Inc. For virus infection, 200 HA
units/ml Sendai virus were added to the target, and cells were then
collected for RNA isolation.
Transfection, Growth and Reporter Assays
Transfection of IB4 cells were achieved by using Amaxa
Nucleofector Device. The 1610
6 cells were transfected with 5 mg
of DNA in solution B and program U20. Transfected cells were
immediately put into 12 wells plates with RPMI plus FBS.
Approximately 70% of cells could be transfected with the protocol.
One day later, live cells were isolated by Ficoll-Paque Plus (GE
Healthcare) following manufacturer’s recommendations. The live
cells were counted and dispensed in culture flask at 3.5610
5 cells/
ml: this was counted as Day 1 after transfection. Everyday, a small
portion of cells were stained with trypan blue and live cells were
counted using the hemocytometer. Statistical analyses of the
differences were determined by paired t test with GraphPad Prism
software version 5.0 (GraphPad Software, Inc., San Diego, CA).
Electroporation (320 V; 925 microfarads) was used for trans-
fection of the DG75 cells as described previously [13,14,36]. A
total 5 mg of DNA was used for transfection of DG75 cells. 1 mgo f
LMP-1-expression plasmids were always used in transfection
because similar LMP-1 expression levels in transfected and EBV
type III latency cells could be achieved under such conditions.
Enrichment for CD-4-positive cells was performed with the use of
anti-CD-4-antibody conjugated to magnetic beads according to
the manufacturer’s recommendation (Dynal, Inc.). DG75 cells
were transfected with CD-4 expression and other plasmids. One
day after the transfection, the cells were used for isolation of CD-4-
positive cells with the use of Dynabeads CD4 (Dynal Inc.) The
transfected cells were incubated with Dynabeads-CD4 at 72 mlo f
beads/10
7 cells for 20–30 min at 4uC with gentle rotation. CD4-
positive cells were isolated by placing the test tubes in a magnetic
separation device (Dynal magnet). The supernatant was discarded
while the CD4-positive cells were attached to the wall of the test
tube. The isolated cells were used to extract total RNAs or prepare
cell lysates immediately.
293T cells were seeded and grown to 40 to 50% confluence in
each well of 12-well dishes (Becton Dickinson labware). For each
well, 293T cells were transfected with 0.2 ug of total DNA mixed
with 4 ul Effectene according to the manufacture’s instructions.
Twenty four hours after transfection, the cells were collected by
centrifuging at 8006g for 5 mins, and washed once with
phosphate-buffered saline (1x PBS). Luciferase activities were
measured using a luciferase assay system (Promega) according to
the manufacturer’s procedure. Data were averaged from the
results of multiple transfections performed in at least three
independent experiments.
Western Blot Analysis with Enhanced
Chemiluminescence (ECL)
Separation of proteins on SDS-PAGE and western blot were
carried out following standard protocol as described [28,37].
RNA Extraction and RNase Protection Assays (RPA)
Total RNA was isolated from cells using the RNeasy total RNA
isolation kit (Qiagen, Valencia, CA) or TRIzol extraction. RPA
was performed with 10 mg of total RNA using the RNase
protection assay kit II (Ambion, Houston, TX) at 55uC.
Sometimes, gradient temperatures were performed for RPA when
difficulties in RPA were encountered [38]. The GAPDH probe
was from U. S. Biochemicals. The probe for IRF-7 (for all splicing
variants) was a described before. To prepare the IRF-7C-specific
RPA probe, the specific region of IRF-7C was amplified by PCR
IRF-7C in Viral Transformation
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CACCCGTACAGC-39 and 59-CGGGAATTCGAGGCTGA-
GACTGCGGAGCG-39) and cloned into pcDNA3 vector (In-
vitrogen). The plasmid was digested by EcoRI, and transcribed
with T7 RNA polymerase. This template would produce a 251-
nucleotide run-off transcript encompassing the splicing junction
region.
NIH 3T3 Cell Transformation Assays
Subconfluent cultures of NIH 3T3 cells seeded in 60-mm-
diameter tissue culture dishes were transfected with 500 ng of
desired expression plasmids by the calcium phosphate method.
Two days after transfection, the cultures were subcultured into
growth medium supplemented with G418 to select for drug-
resistant stably transfected cell populations. NIH 3T3 cells stably
expressing target proteins were pooled and single-cell suspensions
(5610
4 cells per 60-mm-diameter dish) of each cell line were
suspended in growth medium supplemented with 0.3% agar. The
appearance of proliferating colonies of cells was monitored and
quantitated for up to 4 weeks.
Human Tumor Array Analysis
Slides containing multiple tumor specimens were purchased
from NIH Tissue Array Research Program (TARP). Routine
immunostaining protocols were employed for array slides
(TARP3) [28]. The TARP3 slides contain 441 primary tumor
specimens and 50 normal tissues. The primary antibody used for
this study is our polyclonal IRF7C-specific antibody generated in
our laboratory. A Cy-2-labeled donkey anti-rabbit secondary
antibody was purchased from The Jackson Laboratory. Propidium
iodide was from Sigma and used to stain the nuclei. The slides
were examined by confocal microscopy in UNL Microscope
Facility.
Results
IRF-7C Is Associated with EBV Type III Latency
A short ORF and long 3-UTR sequence are characteristic
features to trigger a nonsense-mediated mRNA decay (NMD)
degradation pathway [39]. IRF-7C RNA structure fits the
characters. It is thus important to test if IRF-7C is indeed
expressed in cells. The current available IRF-7 antibodies cannot
distinguish all IRF-7 splicing variants. In order to study the
function of IRF-7C, we have made an antibody specifically for
IRF-7C C-terminal 13-amino acid peptide (Figure 1A, see
Materials and Methods for details). As shown in Figure 1B, while
full-length IRF-7 antibody detected all IRF-7 splicing variants, the
IRF-7C peptide antibody only detected IRF-7C protein. Thus, the
antibody is indeed specific to IRF-7C.
Next, we examined expression of IRF-7C in EBV-positive cell
lines.BL41, BL41-EBV, Sav I and Sav III werechosen as cell linesfor
this analysis. These are genetically identical lines: BL41 is an EBV-
negative BL line and BL41-EBV is its EBV-infected counterpart with
type III latency. Sav I and SavIII have identical genetic background.
S a v eIi sat y p eIl a t e n c yw h i l eS a vI I Ii sat y p eI I Il a t e n c yc e l ll i n e .A s
shown in Figure 1C, IRF-7C protein is highly expressed in EBV type
III latency cells (BL41-EBV and Sav III).
To confirm the association data in Figure 1, we have tested the
RNA expression levels of IRF-7C in these cell lines. A specific
RPA probe was designed for specific detection of the expression of
IRF-7C RNA (Figure 2A, see Materials and Methods for details).
RPA was performed with the IRF-7C-specific plus GAPDH
probes. As shown in Figure 2B, IRF-7C RNA was expressed at
much higher level in BL41 EBV and Sav III, which is in consistent
with protein expression data (Figure 1C). The expression of all
IRF-7 splicing variants is also similar as reported previously (data
not shown, and references [26,30]). Thus, the expression of IRF-
Figure 1. IRF-7C protein is associated with type III latency. A. Schematic diagram of IRF-7C-specific epitope. The open bar represents open-
reading frames (ORF). The expression plasmids were made as shown. The IRF-7C has unique 13 amino-acid (aa), represented by solid bar, at the C-
terminus because the splicing changes the original ORF. The peptide was synthesized according to the last 15-aa sequence in IRF-7C and was used
for antibody production. IRF-7CD is an expression plasmid that lacks the C-terminal 13-aa of IRF-7C. Specific epitope for IRF-7C is shown. The drawing
is not on scale. B. Examination of IRF-7C-specific antibody. 293T cells were transfected with various expression plasmids as shown on the top. The
expression levels of IRF-7C and GAPDH proteins were determined by Western blotting. Left panel: IRF-7C-specific antibody was used. Right panel: full-
length IRF-7 antibody was used. C. IRF-7C protein is highly expressed in cells with EBV type III latency. Cell lysates from the indicated cells lines were
separated by 12% SDS-PAGE. The expression levels of IRF-7C and tubulin proteins were determined by Western blotting. The images in the same box
indicate that they are derived from the same membrane. The identities of proteins are shown.
doi:10.1371/journal.pone.0009459.g001
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protein levels.
IRF-7C Is Associated with EBV Transformation Processes
Because IRF-7 has been shown to be a potential factor in EBV
transformation processes, we thus examined if IRF-7C is involved in
EBV transformation processes. Primary B cells were isolated from
fresh blood by CD19-antibody-conjugated magnetic beads. The
expressionofIRF-7CfromprimaryBcellsofdifferentindividualswas
compared with EBV-transformed B cell lines in vitro (LCL). As
shown in Figure 3, high levels of IRF-7C expression are associated
with EBV-transformed cells. The same cell lysates were also used for
examination of other proteins: the expression of IRF-1, -2, and -3,
STAT-2,and-3isapparentlynotassociatedwiththisprocess[28,35].
The expression of LMP-1 in the EBV transformed cells had been
examined in our previous publication [28]. Thus, IRF-7C protein is
stimulated during EBV transformation in vitro. Because EBV-
transformed LCLs are in type III latency, these data alsoreinforce the
previous notion that IRF-7C is associated with type III latency.
LMP-1 Stimulates the Expression of IRF-7C
Because LMP-1 is the primary inducer of IRF-7, we tested if LMP-
1 is responsible for the induction of IRF-7C. EBV-negative DG75
cells were transfected with LMP-1 or LMP-DM and a CD4-
expression plasmid. LMP-DM is a mutant of LMP-1 that fails to
activate major intracellular signals [30]. The levels of IRF-7C were
determined by RPA after selection of the transfected cells by the use
of CD-4 antibody-conjugated magnetic beads (see Materials and
Methods for details). As shown in Figure 4, LMP-1 expression causes
a marked increase in IRF-7C RNA levels in DG75 cells; however,
LMP-DM was not. Therefore, LMP-1 is probably responsible for the
induction of IRF-7C in EBV type III latency cells.
IRF-7C Has Oncogenic Potential
Because of the fact that IRF-7 has oncogenic potential, we would
like to test if IRF-7C also has a similar property. NIH3T3 cells were
chosen for the analyses. IRF-7C expression plasmid was transfected
into NIH 3T3 cells, and the IRF-7C-expressing cells were selected
in G418-containing medium. Stable cell lines were pooled, and the
expression of IRF-7C was confirmed (data not shown).While vector
control lines showed a limited numbers of colonies, IRF-7C could
induce the growth of NIH 3T3 cells in soft agar assay (Figure 5A).
These data indicate that IRF-7C has oncogenic potential based on
this assay system. We also did the comparative studies on the
potency of transformation with various IRF-7 splicing variants.
However, the expression of IRF-7C was always higher that that of
IRF-7A (data not shown). Thus, we were unable to conclude on
which splicing variant is more potent in oncogenesis.
IRF-7C Partially Rescues the IRF-4-Knockdown-Mediated
Growth Inhibition
Because we have not established a system to knockdown
endogenous IRF-7 specifically, we could not test the role of IRF-
Figure2.ExpressionofIRF-7CRNAisassociatedwithtypeIIIlatency. (A)SchematicdiagramofIRF-7C-specificRPAprobe.ThebarrepresentsORF.
The IRF-7C-specific RPA probe encompasses the splicing junction. The IRF-7-specific probe region for all splicing variants is also shown. The drawing is not
on scale. (B) IRF-7C RNA is highly expressed in cells with EBV type III latency. Total RNAs from the indicated cells lines were used for RPA with IRF-7C and
GAPDH-specific probes. The images in the same box indicate that they are derived from the same gels. The identities of RNAs are shown.
doi:10.1371/journal.pone.0009459.g002
Figure 3. IRF-7C is associated with EBV transformation of
primary B lymphocytes in vitro. Top panel: IRF-7C is highly
expressed in EBV-transformed cells. Primary B cells were isolated from
fresh human blood by the use of CD19 antibody-conjugated magnetic
beads. Lysates from primary B cells from two individuals (lanes 1 and 2)
and EBV-transformed B cell lines (lanes 3–6) were separated by 12%
SDS-PAGE. The expression levels of IRF-7C and GAPDH were determined
by Western blotting. The same membrane was stripped and reprobed
with GAPDH antibody. Bottom panel: relative levels of IRF-7C
expression in EBV transformed cells. The relative levels of IRF-7C
expression (IRF-7C/GAPDH) were obtained by measuring intensity of
IRF-7C and GAPDH from Panel A using ImageJ 1.37v software (NIH).
doi:10.1371/journal.pone.0009459.g003
IRF-7C in Viral Transformation
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variants. However, we have previously shown that IRF-4-
knockdown caused growth inhibition in EBV-transformed cells
[40]. Because all IRFs bind to similar DNA sequences, and IRF-
7C has DNA binding domain, we tested if IRF-7C could rescue
the IRF-4-knockdown-mediated cell growth inhibition. The
expression of IRF-4 in IB4 cells could be specifically inhibited
with transfection of three different siIRF4 expression plasmids
together, and the growth of these cells was significantly inhibited.
Once IRF-7C was co-transfected, the siIRF4-mediated growth
inhibition was partially relieved (Figure 5B). And an IRF-7C
mutant, IRF-7CK92E had no effects. The IRF7C-K92E was
unable to bind to DNA based on EMSA assay ([36], and Data not
shown). These data suggest that IRF-7C has an effect on IRF-4-
knockdown-mediated growth inhibition.
IRF-7C Is Expressed in Lymphoma Specimens
Because we have the specific antibody against IRF-7C, the
expression of the IRF-7C protein in various tumors was
examined in a human tumor array from NCI Tissue Array
Research Program (TARP). The tumor slides (TARP3) con-
tained normal and various tumor specimens (total: 491
specimens). IRF-7C was predominantly expressed in several
tumor specimens (Figure 6), but not in other tumor specimens or
normal tissues. In these tumors, IRF-7C-positive cells are over
25% in tumor areas. Surprising, these IRF-7C-positive speci-
mens are all lymphomas with the limited information provided
by TARP3 (Table 1). Some other specimens also showed
sporadic IRF-7C-positive cells (data not shown). Thus, IRF-7C
is apparently highly expressed in some primary tumors, although
the linkage of IRF-7C and EBV in vivo has not yet been
established in this study.
IRF-7C Represses the Transactivation of IFN Promoter of
IRF-7
We next examined if IRF-7C is able to inhibit the
transactivation activity of IRF-7 (IRF-7A). IRF-7 and IRF-7C
were co transfected into 293T cells along with the IFN-b
promoter reporter construct. IRF-7C was able to repress the
transactivation function of IFN-b-promoter activity by IRF-
7(Figure 7A). Also, the repression was associated with the ability
o ft h eI R F - 7 Ct ob i n dt oD N Aa st h eD N A - b i n d i n gm u t a n to f
IRF-7C is unable to repress the activation (Figure 7B). In
addition, IRF-7C was able to repress the Sendai virus induced
activation of IFN-b promoter reporter construct (data not shown,
also [41]). Thus, IRF-7C is able to block the transactivation
function of IRF-7.
IRF-7C Is Associated with Other IRF-7 Splicing Variants
We next examined the relation among the expression of IRF-7C
and other IRF-7 splicing variants. With limited experiments, we did
not observe any splicing-specific regulation of IRF-7C by EBV
Figure 4. LMP-1 stimulates the expression of IRF-7C. DG75 cells
were transfected with pcDNA3, LMP-1, or LMP-DM expression plasmids.
The transfected cells were isolated, and total RNAs were isolated and
used for RPA with IRF-7C and GAPDH-specific probes. Yeast RNA was
used as negative control. Specific protections of IRF-7C and GAPDH
RNAs are indicated.
doi:10.1371/journal.pone.0009459.g004
Figure 5. IRF-7C has oncogenic potential. (A) IRF-7C causes anchorage-independent growth of NIH 3T3 cells. A soft-agar assay was used for an IRF-7C
stably expressing cell line established in NIH 3T3 cells. The numbers are averages from three independent experiments and standard deviations are also
shown.(B)IRF-7CpartiallyrestoresthegrowthpropertyofIRF-4-knockdowncells.KnockdownofIRF-4inhibitsthegrowthofEBV-transformedcells.AnEB V -
transformed cell line (IB4) was transfected with shLuc, shIRF4, shIRF4 plus IRF-7C, or shIRF4 plus IRF7C-K92E by use of an Amaxa Nucleofector device
respectively. One day after transfection, live cells were isolated and seeded. At the indicated days after transfection, surviving cells were enumerated by
trypan blue exclusion. Each point represents the number of live cells (mean 6 standard deviation) from three different counts. The difference between
shIRF4, and shIRF4+IRF-7C is statistically significant (p=0.0071). One representative of three independent experiments is shown.
doi:10.1371/journal.pone.0009459.g005
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as well as viral infection induces the expression of IRF-7. We thus
examined the expression of IRF-7C and its relation to other IRF-7
splicing variants during those induction processes. THP-1 cells were
treated with IFN-a or Sendai virus. Cells were collected and RNA
was isolated at various times. The same RNAs were used for RPA
for the detection of IRF-7C as well as IRF-7(all variants)
respectively. As shown in Figure 8, IRF-7C is associated with other
IRF-7 splicing variants, and no obvious splicing-specific expression
was observed in either IFN-a or Sendai virus treated cells.
Discussion
In this report, we have examined the possible role of the IRF-
7C, one splicing variant of IRF-7, in EBV transformation of
human B lymphocytes. First of all, because IRF-7C mRNA
structure apparently fits the two hallmarks for NMD degradation
[39], it is thus necessary to test the existence of IRF-7C under
physiological conditions. Our data clearly indicate that IRF-7C
protein is indeed expressed in cells both in pathogenic and
physiological conditions. IRF-7C RNA is expressed proportionally
to other IRF-7 variants’ RNA in several induction conditions.
Thus, NMD-mediated mRNA decay seems not a major player in
the regulation of IRF-7C expression.
With the IRF-7C specific antibody, we have found that IRF-7C
is associated with EBV transformation in primary B cells (Figure 3).
The basis for the association is apparently related to the fact that
IRF-7C is associated with EBV Type III latency (Figures 1 and 2),
and EBV LMP-1 is at least partially responsible for the induction
of IRF-7C in B cells (Figure 4). Because LMP-1 is required for
EBV transformation, and LMP-1 is a membrane protein that
requires cellular proteins for its signaling and transformation
functions, it is thus suggested that IRF-7C is involved in the EBV-
mediated transformation of primary B cells. Furthermore, IRF-7C
is able to transform NIH 3T3 cells (Figure 5A), and partially rescue
IRF-4-knockdown-mediated cell growth inhibition (Figure 5B).
Because specific knockdown of endogenous IRF-7 in EBV-
transformed cells has not been established yet, the direct role of
IRF-7C in EBV transformation without other IRF-7 splicing
variants is still not available. However, all these data collectively
Figure 6. Expression of IRF-7C in human tumor specimens. The IRF-7C expression in tumor arrays was detected by staining with the IRF-7C-
specific antibody and a Cy-2-labeled donkey anti-rabbit secondary antibody, followed by examination in confocal microscope. Propidium iodide was
used to stain the nuclei. The colors were artificially mounted to facilitate viewing. Panel A: IRF-7C in green; Panel B: nuclei in red; and Panel C shows
the combination of IRF-7C and nuclei. Two tumor specimens are shown: top: YY-00-0302; bottom: YY-00-0513.
doi:10.1371/journal.pone.0009459.g006
Table 1. Expression of IRF-7C in human tumor specimens.
Block Code Tumor Type Sex Age Other Information
YY-00-0513 Lymphoma M 59 IPOX positive CD5, CD20, CD23
YY-00-0509 Lymphoma M 54 No information
YY-00-0126 Lymphoma F 74 Flow, positive for CD10, CD19, CD20, lambda
YY-00-0135 Lymphoma F 39 IPOX positive for CD20, CD30, negative for CD3, CD15, EMA
YY-00-0302 Lymphoma F 20 Hodgkins Lymphoma, IPOX positive CD30, CD15, CD20, status post treatment
YY-00-0297 Lymphoma M 69 spleen, flow negative for CD5 and CD10
The tumor array (TARP3) was obtained from NIH TARP. The expression of IRF-7C was determined by the use of immunostaining technique. The additional information
was obtained from the provider.
doi:10.1371/journal.pone.0009459.t001
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in EBV transformation process.
We also examined the expression of IRF-7C in a tumor array
that contains more than 400 different primary tumor specimens,
and our data indicated that several lymphoma tissues expressed
IRF-7C extensively (Figure 6 and Table 1). Because LMP-1
expression is sporadic in tumor cells, the connection between
LMP-1 and IRF-7C in vivo is not clearly established (data not
shown). Sporadic IRF-7C-espression cells in some other tumors
are also observed. Thus, IRF-7C might also play a role in the
development of other tumors, not necessarily only associated with
EBV.
IRF-7C has the DNA binding domain only [23]. It is known
that the DNA binding domain of IRF-2 alone is able to transform
at least rodent cells, possibly through competition with other IRFs
for binding to the same or similar DNA sequences [42]. It is thus
possible that IRF-7C is also using the similar mechanism. This
notion is supported by the fact that the IRF-7C-mutant, IRF7C-
K92E, failed to rescue the IRF4-knockdown-mediated cell growth
inhibition (Figure 5B).
IRF-7C is associated with other IRF-7 variants in EBV
transformed cells (Figures 1 and 2; Also data not shown, and
references [26,30,37]), as well as in IFN-treated or Sendai virus-
infected cells (Figure 8). Thus, IRF-7C is apparently associated
with IRF-7 in those situations examined without a specific splicing-
specific expression. This close association among IRF-7C and
other IRF-7 variants suggests that IRF-7C and IRF-7 may
collectively contribute to the transformation processes of EBV.
Other than in viral transformation, IRF-7C may contribute to the
regulation of both viral and cellular promoters, notably EBV Qp.
IRF-7C inhibits the promoter activity of Qp [23]. The expression
of IRF-7C is inversely associated with Qp activity (Qp is inactive
Figure 7. IRF-7C inhibits IRF-7-mediated transactivation of IFN promoter. A. IRF-7C inhibits the IRF-7-mediated activation of IFN-b reporter
construct. 293T cells were transfected with 0, 50, 100, and 200 ng of IRF-7C (lanes 1–4 respectively) plus IFN-b promoter reporter construct and b-gal
expression plasmids. Lanes 5–8, based on the same conditions of lanes 1–4, IRF-7A plasmid (100 ng) was added and also co-transfected into 293T
cells with other plasmids. (B) DNA-binding of IRF-7C is required to inhibit the activation of IFN-b promoter. 293T cells were transfected with pcDNA3,
IRF-7A (100 ng) IRF-7A+IRF-7C (200 ng), and IRF-7A+IRF7C-K92E (200 ng) respectively (lanes 1–4), along with IFN-b promoter reporter construct and
b-Gal expression plasmids. Luciferase and b-gal activities were measured at 24 h after transfection. The relative folds of activation of promoter
constructs are shown with standard deviations. One representative of three independent experiments is shown.
doi:10.1371/journal.pone.0009459.g007
Figure 8. Correlative expression of IRF-7C and IRF-7. A. IRF-7 RNA expression upon IFN treatment. THP-1 cells were treated with IFN-a at
100 u/ml at the indicated times. Cells were collected at 0, 2, 4, 8, 12 and 24 hrs after treatment. Total RNAs were extracted with TRIzol (Invitrogen),
and used for RPA with IRF-7C, IRF-7 (all splicing variants) and GAPDH probes. B. IRF-7 RNA expression upon virus infection. THP-1 cells were infected
with Sendai virus, and cells were collected at 0, 2, 4, 8, 12 and 24 hrs post infection. Total RNAs were extracted with TRIzol (Invitrogen), and used for
RPA. The images in the same box indicate that they are derived from the same gels. The identities of RNAs are shown.
doi:10.1371/journal.pone.0009459.g008
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both IRF-7 and IRF-7C may contribute the inactivation of Qp in
type III latency.
IRF-7C is able to inhibit the function of IRF-7 in transactiva-
tion IFN promoter reporter constructs (Figure 7). Given the facts
that: 1) IRF-7 is highly expressed and activated in EBV
transformed cells [21,23,43]; 2) activated (or over-expression of)
IRF-7 may activate endogenous type I IFNs [41,44,45]; and 3)
EBV-transformed cells do not produce type I IFNs [13,14], it is
possible that IRF-7C could be used by the cells to block the
spontaneous IFN production during EBV transformation. This
might be important for viral transformation as IFNs are a factor in
controlling the transformation process: EBV transformation is
inhibited by IFNs and the virus encodes genes that specifically
nullify the functions of IFNs [46,47,48,49,50].
Furthermore, it is well known that IFN treatment increases IRF-
7 levels [45,51,52], and IFN-treated cells do not produce type I
IFNs [53,54,55]. Therefore, IRF-7C induced by IFN-treatment
might play a similar role in repressing spontaneous IFN
production processes during IFN treatment. Unfortunately, due
to the fact that a splicing-specific knockdown of IRF-7C is not
available, this notion is hard to verify experimentally.
Thus, our data collectively suggest that EBV may use splicing
variants of IRF-7 for its transformation process in two strategies: to
use the oncogenic properties of various IRF-7 splicing variants to
promote transformation process, but uses one of its splicing
variants (IRF-7C) to block the detrimental function of IRF-7 in
IFN-induction. In addition to IRF-7C, other IRFs, such as IRF-4,
might also be involved in the inhibition of IFN processes. IRF-4 is
a known inhibitor for IFN production, and a known key player in
EBV transformation [40].
IRFs and EBV transformation have close relations. IRFs are
used by EBV to regulate both viral and cellular factors that are
involved in EBV latency and transformation [14,26,37,43,56,57].
Other than IRF-7, IRF-4 and IRF-5 are also associated with EBV
transformation. IRF-5, likely a tumor suppressor [58,59,60,61,62],
is highly expressed in EBV transformed cells and, together with
IRF-4, may be involved in the EBV-mediated regulation of Toll-
like receptor 7 activities [56]. Thus it is apparent that EBV induces
a balanced expression of IRFs during EBV transformation. With
reciprocal inhibition and/or activation among these factors, EBV
may lead the infected cell to apoptosis or proliferation for its own
benefits in various microenvironments for the survival of the virus
in vivo. The work here has expanded our knowledge about IRFs
and EBV transformation and provides more details in the
potential balanced actions among various IRFs in EBV transfor-
mation processes.
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